Navigation Links
Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
Date:11/1/2007

ents with stable coronary artery disease.

"I am very pleased with the results of this first clinical experience with the REG1 system during a stent procedure. We anticipate this drug will fulfill multiple unmet needs in the care of heart patients," stated Mauricio Cohen, MD, the Director of Cardiology Clinical Trials at the University of North Carolina and Principal Investigator of the REVERSAL-PCI study. "The lack of a safe and at the same time efficacious reversible blood thinner has been a major problem for cardiologists performing invasive catheterization procedures. We are hopeful that this agent will revolutionize the approach to anticoagulation during catheter-based interventions and the care of heart attack patients."

Currently, heparin and protamine are the only approved therapeutic/antidote drug pair used in surgical procedures, such as PCI. However, these drugs have well-known limitations, including the risk for developing heparin-induced thrombocytopenia (with or without thrombosis), as well as protamine-associated side effects, such as anaphylaxis and systemic hypotension.

About REG1 Anticoagulation System

Regado's lead product candidate, REG1, is the first specific, direct-acting, antidote-controlled anticoagulant ever described. Regado is developing REG1 for use in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures. These procedures, which include coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI), put patients at a high-risk for therapy-related bleeding complications. REG1 is being developed initially to increase therapeutic flexibility and improve patient outcomes in coronary revascularization procedures.

REG1 is a two-component system, consisting of an aptamer-based anticoagulant and its matched antidote. The REG1 anticoagulant component (RB006) is a single-stranded, nucleic acid aptamer. RB006 selectively and potently binds to and inhibits
'/>"/>

SOURCE Regado Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
5. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. Lux Biosciences Investigational Therapy for Uveitis, LX211, is Subject of Two Presentations at Key Ophthalmology Meeting, ARVO 2007
9. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
10. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Chindex International, Inc. ("Chindex" or the "Company") ... special meeting of stockholders held today, the Company,s stockholders ... by and among the Company, Healthy Harmony Holdings, L.P. ... is an affiliate of TPG, Shanghai Fosun Pharmaceutical (Group) ... the CEO of the Company. The Merger ...
(Date:9/16/2014)... 2014 Research and Markets has announced ... report to their offering. Animal vaccines ... Animal vaccines are generally prepared from weakened or dead microbes ... state. Some of the animal vaccines are also formulated using ... or toxic components. These components act as ...
(Date:9/16/2014)... 2014 QPID Health , a leader in ... in Boston and their first West ... at 175 Franklin Street in Boston , ... Health,s new Southern California office will ... will help meet the demands of customers nationwide.  Both new ...
Breaking Medicine Technology:Chindex Stockholders Approve Merger 2Chindex Stockholders Approve Merger 3Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3QPID Health Announces Major Office Expansion in Boston and Opens Facility in San Diego 2
... New data being presented at the American ... in San Diego showed that treatment with KAPIDEX(TM) ... resulted in a statistically significant greater percentage of ... reflux disease (GERD), compared to placebo (p<0.001). In ...
... for Medco Health Solutions, Inc. (NYSE: MHS ) ... , Timothy Wentworth, Medco,s group president for employer accounts, ... Wednesday, November 4, 2009 at 2:10 p.m. ET at ... Snow Jr., Medco chairman and CEO, will address the ...
Cached Medicine Technology:New Study Results Analyzed the Use of KAPIDEX(TM) (dexlansoprazole) for Nighttime Heartburn in Adults with Non-Erosive GERD 2New Study Results Analyzed the Use of KAPIDEX(TM) (dexlansoprazole) for Nighttime Heartburn in Adults with Non-Erosive GERD 3Medco to Present at November 2009 Investor Conferences 2
(Date:9/16/2014)... (PRWEB) September 16, 2014 Advanced Fertility ... recently named by Houstonia Magazine as one of the ... by Houstonia Magazine - a metropolitan magazine serving the ... area and recognize them for their outstanding services. This ... 2014 edition of Houstonia Magazine — a special publication ...
(Date:9/16/2014)... great promise in helping people to reach their ... help the wearers improve their wellness by constantly ... is organized into companion computer programs and mobile ... growing market for these devices, researchers at the ... 13 of these activity monitors, such as those ...
(Date:9/16/2014)... A new study found that fractional flow ... true coronary bifurcation lesions yields similar outcomes to ... trial is the first study to compare FFR-guided ... today at the 26th annual Transcatheter Cardiovascular Therapeutics ... Foundation (CRF), TCT is the world,s premier educational ...
(Date:9/16/2014)... Ind. - Ensuring that corn absorbs the right balance ... global yields, a Purdue and Kansas State University study ... 150 studies from the U.S. and other regions showed ... which corn plants took up key nutrients at specific ... 5-to-1 and nitrogen and potassium at a ratio of ...
(Date:9/16/2014)... Who:, The Pulmonary Hypertension Association (PHA), ... Children’s Hospital Colorado are hosting Colorado PH in the ... association that works to find ways to prevent and cure ... affects the functioning of the heart and can lead to ... years. , What:, Colorado PH in the Park 2014 ...
Breaking Medicine News(10 mins):Health News:Dr. Michael Allon Receives Esteemed Recognition 2Health News:Do wearable lifestyle activity monitors really work? 2Health News:Do wearable lifestyle activity monitors really work? 3Health News:Results of DKCRUSH-VI trial reported at TCT 2014 2Health News:Boosting global corn yields depends on improving nutrient balance 2Health News:Boosting global corn yields depends on improving nutrient balance 3Health News:Help Fight Pulmonary Hypertension at the Colorado PH in the Park 2014 2
... decided to launch a ban on sale of Colas and junk ... and junk food may be out of school canteens across the ... are bad for children’s health. Hence, we want to ban the ... with Union Human Resource Development Ministry on the legal aspects of ...
... cancer is available in Singapore for those between the ... ,The Health Sciences Authority (HSA) gave its approval ... similar vaccine, Cervarix, from competitor GlaxoSmithKline, is awaiting approval ... health breakthrough, said Tay Eng Hseon, a doctor at ...
... gas tragedy survivors' organisations claimed //to have seized a ... medical stores of the Bhopal Gas Tragedy Relief and ... organisations, working for the victims of the world's worst ... their expiry date," Rachna Dhingra of Bhopal Group of ...
... donated $30 million to University Hospitals (UH), a major ... turned his graduate thesis into a global automotive business ... himself, his wife Usha and their family, in support ... 2010. ,In recognition of the Ahuja family's ...
... treatment to remove lead from the body -- can significantly ... a// Cornell study of young rats finds. ,However, ... of autistic children, the researchers say that when rats with ... chemical, they showed declines in their learning and behavior that ...
... on women in their 70's to observe the relationship between ... followed nearly 12,000 women in// their 70’s over a 6 ... for 3-6 days/week, depending on alcoholic content) may lead to ... ,This study was published in Journal of the American ...
Cached Medicine News:Health News:Indian American Donates $30 Mn to Healthcare System 2Health News:Pros and Cons of Therapy for Lead Exposure 2
... The 50 psi MaxiCompressor, the ... to run 24 hours a ... It features a tamper-proof locking ... unintentional increases or decreases in ...
... popular and competitively priced SportNeb features ... Design enhancements include a neb kit ... black carry bag. The color SportNeb ... SportNeb also offers private labeling opportunities ...
... Treatment Compressor (230V). Same performance specifications as ... wide selection of adult and pediatric mask/nebulizer ... in a variety of international voltages and ... important part of managingthe disease state of ...
The 16 liter Laparoscopy Insufflator combines high safety and precise pressure control with simple operation....
Medicine Products: